The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2019 | Neoadjuvant atezolizumab in NSCLC

Name: Neoadjuvant atezolizumab in NSCLC
Uploaded: 2019-06-01T00:00:00Z
Duration: 3 min 7 s
Description: David Kwiatkowski, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outline a study investigating the use of neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

David Kwiatkowski • 1 Jun 2019

ASCO 2019

Lung Cancer Atezolizumab

David Kwiatkowski, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outline a study investigating the use of neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.